Esperion Therapeutics (ESPR) Appoints Seth H.Z. Fischer to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Esperion Therapeutics (ESPR) Tops Q3 EPS by 18c; Reports Cash and Cash Equivalents of $153.7M
November 2, 2021 7:17 AM EDTEsperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($2.62), $0.18 better than the analyst estimate of ($2.80). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $12.85 million.
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
... More